Characterizing CDK12-Mutated Prostate Cancers.

PURPOSE: CDK12 aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated mCRPC, presenting clinical, genomic, and tumor-infiltrating lymphocyte data. EXPERIMENTAL DESIGN: Patients with...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Rescigno, Pasquale, Gurel, Bora, Pereira, Rita, Crespo, Mateus, Rekowski, Jan, Rediti, Mattia, Barrero, Maialen, Mateo, Joaquin, Bianchini, Diletta, Messina, Carlo, Fenor de la Maza, Maria D., Chandran, Khobe, Carmichael, Juliet, Guo, Christina, Paschalis, Alec, Sharp, Adam, Seed, George, Figueiredo, Ines, Lambros, Maryou, Miranda, Susana, Ferreira, Ana, Bertan, Claudia, Riisnaes, Ruth, Porta, Nuria, Yuan, Wei, Carreira, Suzanne, de Bono, Johann S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7855716/
https://ncbi.nlm.nih.gov/pubmed/32988971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-2371
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg